Tilray becomes first and only company with both flower and oil
medical cannabis products available in the German market
NANAIMO, British Columbia--(BUSINESS WIRE)--Sep. 13, 2018--
Inc., (NASDAQ: TLRY), a global leader in cannabis research,
cultivation, production and distribution, today announced that it has
received necessary regulatory permits in Canada and Germany to export
medical cannabis flower for distribution to German patients.
Tilray previously announced
the first-ever export of medical cannabis oil to Germany for nationwide
distribution in pharmacies. Tilray’s full-spectrum cannabis extracts
became available in German pharmacies nationwide through partnerships
with leading German pharmaceutical wholesalers NOWEDA, GEHE, Alliance
Healthcare, Pharma Privat and Phoenix in cooperation with pharma
logistics partner Paesel + Lorei.
The export of Tilray’s whole flower medical cannabis products will make
Tilray the first and only medical cannabis company with a differentiated
product offering of both full-spectrum oils and whole flower, including
some of the highest potency products available in the German medical
market. Certain patient populations with specialized conditions require
higher potency THC medical cannabis as treatment. These patients will
now have access to products that were previously unavailable to them in
“Today’s announcement marks another milestone for Tilray as we expand
operations in the European Union,” said Brendan Kennedy, Chief Executive
Officer, Tilray. “We are proud to be able to offer access to
differentiated high-quality, pharmaceutical-grade medical cannabis
products to patients in need.”
Tilray became the first medical cannabis producer in North America to be
GMP certified in December 2016. GMP certification is the most rigorous
standard that manufacturers of medical products can meet in their
production processes, and it is intended to provide regulators and
health care providers in countries new to medical cannabis with
certainty that Tilray products are the safe and smart choice. GMP
certification is enabling Tilray to expand the international
distribution of its products.
More details on how patients in Germany can access Tilray’s whole flower
products will be released later this year.
a global pioneer in the research, cultivation, production and
distribution of medical cannabis and cannabinoids currently serving tens
of thousands of patients in eleven countries spanning five continents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912006084/en/
Source: Tilray, Inc.
Chrissy Roebuck, +1-416-560-5712
Petzold, +49 40 899699 230